Saurabh Johri | Protein Conjugation Technologies and Next-Generation Therapeutics
Saurabh Johri joins Executive Insights for Life Sciences Innovators to discuss protein conjugation technologies, therapeutic innovation, and the future of next-generation biologic medicines.
Prefer audio only? Listen to this episode on Spotify.
Episode Overview
In this episode, Saurabh Johri discusses how Catena Biosciences is advancing protein conjugation technologies designed to enable the next generation of therapeutics. The conversation explores platform innovation in biotechnology, the growing importance of precision conjugation methods, and the opportunities these technologies may create across a range of therapeutic applications.
Key Themes
- Protein conjugation technologies
- Next-generation biologic therapeutics
- Platform innovation in biotechnology
- Precision engineering of therapeutic molecules
- Commercial strategy for emerging biotech platforms
- The future of therapeutic development and delivery
Why This Matters for Life Sciences Leaders
Platform technologies often play a critical role in advancing the next wave of therapeutic innovation. As biotechnology companies seek more precise and effective ways to engineer medicines, leaders must evaluate how enabling technologies can create competitive advantages, accelerate development, and unlock new opportunities across multiple therapeutic areas. The conversation highlights the strategic, scientific, and commercial considerations involved in building scalable platform companies in life sciences.
Guest Link
More from Executive Insights
Explore more conversations with life sciences founders, CEOs, investors, and operators on the Executive Insights for Life Sciences Innovators podcast.
